Ms. Celia Economides reports
AURINIA ESTABLISHES AT-THE-MARKET FACILITY
Aurinia Pharmaceuticals Inc. has entered into an
open market sale agreement with Jefferies
LLC pursuant to which the company may from time to
time sell, through at-the-market (ATM) offerings with Jefferies
acting as sales agent or directly to Jefferies acting as principal, such
common shares in the capital of the company as
would have an aggregate offering price of up to $30-million (U.S.). Aurinia
has also filed a prospectus supplement with securities regulatory
authorities in Canada in the provinces of British Columbia, Alberta and
Ontario, and with the United States Securities and Exchange Commission,
which supplements Aurinia's short form base shelf prospectus dated March
26, 2018, and Aurinia's shelf registration statement on form F-10 dated
March 26, 2018, declared effective on March 29, 2018. The listing of any
shares sold pursuant to the ATM offering is subject to the approval of
the Toronto Stock Exchange and Nasdaq. Jefferies, at Aurinia's
discretion and instruction, will use its commercially reasonable efforts
to sell the common shares at market prices from time to time. Sales in
the ATM offering will only be conducted in the United States through
Nasdaq or another exchange at market prices. No sales will be conducted
in Canada or through the Toronto Stock Exchange.
Aurinia currently intends to use the proceeds from sales related to the
ATM offering, if any, to fund its operations, including the clinical
development and commercial production of voclosporin (whether for lupus
nephritis (LN) or other indications), regulatory, premarketing and
commercialization preparation activities for potential approval of
voclosporin, primarily for LN but also potentially for other voclosporin
indications, business development opportunities such as additional
product in-licensing transactions, additional clinical trials or
acquisitions of other businesses or products, capital expenditures and
working capital.
Copies of the prospectus supplement and the accompanying prospectus
relating to these securities may be obtained by contacting Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Ave., 2nd Floor, New York, N.Y., 10022, USA, or by telephone at 877-821-7388.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company
focused on developing and commercializing therapies to treat targeted
patient populations that are suffering from serious diseases with a high
unmet medical need. The company is currently developing voclosporin, an
investigational drug, for the potential treatment of lupus nephritis,
focal segmental glomerulosclerosis and dry-eye syndrome. The company is
headquartered in Victoria, B.C.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.